Europe’s Unified Patent Court Postpones Opening & Sunshine Period
EPO’s Transitional Measures Remain Unchanged
Executive Summary
Patent applicants are being given an extra two months to equip themselves with the tools they will need to use the UPC’s electronic case management system.
You may also be interested in...
EPO Supports Early Unitary Patent Uptake From 1 January
The European Patent Office has adjusted the starting date of its transitional measures for applicants that want their patent to have unitary effect under the coming Unified Patent Court system.
EU CHMP Opinions and MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
New EU Filings
Omaveloxolone, Reata Pharmaceuticals’s orphan drug for treating patients with Friedreich’s ataxia, is among the latest drugs that have been filed for review by the European Medicines Agency for potential EU marketing approval.